In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R )-4-Fluoroglutamine

Preclinical and trial data support fluorine 18–(2S,4R)-4-fluoroglutamine (FGln) avidity as a PET biomarker of glutamine flux and metabolism and suggest possible correlations between tumor FGln PET phenotype, oncometabolic genotype, and tumor aggressiveness.